Trial Profile
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Sep 2022
Price :
$35
*
At a glance
- Drugs N acetyl D mannosamine (Primary)
- Indications Kidney disorders
- Focus Adverse reactions
- 06 Jun 2018 Status changed from recruiting to completed.
- 07 Feb 2018 Planned End Date changed from 31 Jan 2018 to 31 Jan 2019.
- 07 Feb 2018 Planned primary completion date changed from 31 Jan 2018 to 31 Jan 2019.